Management of Medical Morbidities and Risk Factors Before Surgery: Smoking, Diabetes, and Other Complicating Factors

ABSTRACT

Patients interested in elective cosmetic procedures often have comorbidities and suffer from medical problems that influence the operative plan and surgical outcome. In the history and physical examination, it is important for the surgeon to identify these areas and be familiar with the associated risks in relation to the planned cosmetic procedure. Common problems that influence plastic surgery and wound healing in general include cigarette smoking, diabetes mellitus, and management of common medications. Smoking is the most common cause of preventable death in the United States today. In addition to its impact on every organ system, it has many detrimental effects on wound healing. Patients judge the results of a cosmetic procedure by symmetry, contour, and minimal scarring; each area is adversely affected by cigarette smoke. In the article “The pathophysiology of the toxins in cigarette smoke” this is outlined, and their particular influence on poor wound healing is highlighted. Techniques for smoking cessation are explained and general guidelines to optimize the outcomes of cosmetic procedures on smokers are described. Complications of diabetes mellitus are seen in heart disease, stroke, blood pressure, ocular disease, kidney failure, peripheral vascular disease, and poor wound healing. There are more than 20 million diabetics in the United States today, and plastic surgeons must be aware of the pathophysiology and impact of diabetes on wound healing and recovery after cosmetic procedures. The normal stages of wound healing are described, and the commonly accepted molecular basis for poor healing and increased infection in diabetics is discussed. The cosmetic surgeon must be aware of these added risks and make his or her patients aware preoperatively. Further, the importance of tight glycemic control in the perioperative period is explored. The question of continuation of home medications during the perioperative period is a complicated issue. Although most medications are safe to take with sips of water several hours before a procedure, some are more controversial. The use of psychotropic medication including antidepressants is gaining popularity. These medications alter the levels of neurotransmitters in the central nervous system, and the combination with anesthetic agents used in the operating room is discussed. Oral contraceptive pills and hormone replacement therapy are commonly used agents in the cosmetic surgery population. In light of their association with venous thromboembolism, recommendations for use in perioperative period are discussed.

KEYWORDS

Cosmetic surgery - medical conditions - smoking - diabetes - psychotropic medication - estrogenic medication

REFERENCES

• 1 Center for Disease Control and Prevention . Cigarette smoking among adults-United States, 2004.  Morbidity and Mortality Weekly. 2005;  54 1121-1148
• 2 Federal Trade Commission .Federal Trade Commission Issues Cigarette Report for 2003. August 9, 2005
• 3 Krupski W C. The peripheral vascular consequences of smoking.  Ann Vasc Surg. 1991;  5 291-304
• 4 Krueger J K, Rohrich R J. Clearing the smoke: the scientific rationale for tobacco abstention with plastic surgery.  Plast Reconstr Surg. 2001;  108 1063-1073
• 5 Jonderko G, Podkowka J, Dabrowski Z, Wegiel A, Zurkowski A. Effect of smoking on cutaneous blood supply as determined by the measurement of heat conductivity coefficient.  Pol Med J. 1966;  54 937-943
• 6 Goldminz D, Bennett R G. Cigarette smoking and flap and full thickness graft necrosis.  Arch Dermatol. 1991;  127 1012-1015
• 7 Riefkohl R, Wolfe J A, Cox E B et al.. Association between cutaneous occlusive vascular disease, cigarette smoking, and skin slough after rhytidectomy.  Plast Reconstr Surg. 1986;  77 592-595
• 8 Wong L S, Green H M, Feugate J E et al.. Effects of “second hand” smoke on structure and function of fibroblasts, cells that are critical for tissue repair and remodeling.  BMC Cell Biol. 2004;  51 13
• 9 Fang Y, Svoboda K H. Nicotine inhibits myofibroblast differentiation in human gingival fibroblasts.  J Cell Biochem. 2005;  95 1108-1119
• 10 Chang L D, Buncke G, Slezak S et al.. Cigarette smoking, plastic surgery and microsurgery.  J Reconstr Microsurg. 1996;  12 467-474
• 11 Nolan J, Jenkins R A, Kurihara K et al.. The acute effects of cigarette smoke exposure on experimental skin flaps.  Plast Reconstr Surg. 1985;  75 544-551
• 12 Craig S, Rees T D. The effects of smoking on experimental skin flaps in hamsters.  Plast Reconstr Surg. 1985;  75 842-846
• 13 Rees T D, Liverett D M, Guy C L. The effect of cigarette smoking on skin-flap survival in the face lift patient.  Plast Reconstr Surg. 1984;  73 911-915
• 14 Spear S L, Ducic I, Cuoco F, Hannan C. The effect of smoking on flap and donor-site complications in pedicled TRAM breast reconstruction.  Plast Reconstr Surg. 2006;  116 1873-1881
• 15 Chang D W, Reece G P, Wang B et al.. Effect of smoking on complications in patients undergoing free TRAM flap breast reconstruction.  Plast Reconstr Surg. 2000;  105 2374-2380
• 16 Kroll S S. Necrosis of abdominoplasty and other secondary flaps after TRAM flap breast reconstruction.  Plast Reconstr Surg. 1994;  94 637-643
• 17 Manassa E A, Hertl C H, Olbrish R R. Wound healing problems in smokers and nonsmokers after 132 abdominoplasties.  Plast Reconstr Surg. 2003;  111 2082-2087
• 18 Rohrich R J. Cosmetic surgery and patients who smoke: should we operate?.  Plast Reconstr Surg. 2000;  106 137-138
• 19 Rohrich R J, Coberly D M, Kreuger J K et al.. Planning elective operations on patients who smoke: survey of North American plastic surgeons.  Plast Reconstr Surg. 2002;  109 350-355
• 20 Myles P S, Leslie K, Angliss M et al.. Effectiveness of bupropion as an aid to stopping smoking before elective surgery: a randomized controlled trial.  Anaesthesia. 2004;  59 1053-1058
• 21 Centers for Disease Control and Prevention .National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2005. Atlanta, GA; US Department of Health and Human Services, Centers for Disease Control and Prevention 2005
• 22 Centers for Disease Control and Prevention .National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2003. Atlanta, GA; US Department of Health and Human Services, Centers for Disease Control and Prevention 2003
• 23 Brunicardi F C, Andersen D K, Billiar T R et al.. Schwartz's Principles of Surgery. 8th ed. New York; McGraw-Hill 2006
• 24 Rohrich R J, Robinson J B. Selected Readings in Plastic Surgery: Wound Healing. Vol 9, No 3 1999
• 25 Lerman O Z, Galiano R D, Armour M et al.. Cellular dysfunction in the diabetic fibroblast.  Am J Pathol. 2003;  162 303-312
• 26 Algenstaedt P, Schaefer C, Biermann T et al.. Microvascular alterations in diabetic mice correlate with level of hyperglycemia.  Diabetes. 2003;  52 542-549
• 27 Terashi H, Izumi K, Deveci M et al.. High glucose inhibits human epidermal keratinocyte proliferation for cellular studies on diabetes mellitus.  Int Wound J. 2005;  2 298-304
• 28 Rohrich R L, Rios J L. The role of prophylactic antibiotics in plastic surgery: whom are we treating?.  Plast Reconstr Surg. 2003;  112 617-618
• 29 Peled I J, Dvir G, Berger J et al.. Prophylactic antibiotics in aesthetic and reconstructive surgery.  Aesthetic Plast Surg. 2000;  24 299-302
• 30 Guyuron B, Raszewski R. Undetected diabetes and the plastic surgeon.  Plast Reconstr Surg. 1990;  86 471-474
• 31 Huyse F J, Touw D J, VanSchijndel R S et al.. Psychotropic drugs and the perioperative period: a proposal for a guideline in elective surgery.  Psychosomatics. 2006;  47 8-22
• 32 Scher C S, Anwar M. The self-reporting of psychiatric medications in patients scheduled for elective surgery.  J Clin Anesth. 1999;  11 619-621
• 33 Center for Disease Control and Prevention .National Center for Health Statistics. http://www.cdc.gov 2005
• 34 Clagett G P, Anderson F A, Geerts W et al.. Prevention of venous thromboembolism.  Chest. 1998;  114(5 Suppl) 531S-560S
• 35 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception . Venous thromboembolic disease and combined oral contraceptives: results of an international multicenter case-controlled study.  Lancet. 1995;  133 1575-1582
• 36 Grodstein F, Stampfer M J, Goldhaber S Z et al.. Prospective study of exogenous hormones and risk of pulmonary embolism in women.  Lancet. 1996;  348 983-987
• 37 Hulley S, Grady D, Bush T et al.. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group.  JAMA. 1998;  280 605-613
• 38 Grady D, Werger N K, Herrington D et al.. Post menopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/Progestin Replacement Study.  Ann Intern Med. 2000;  132 689-696
• 39 Daly E, Vessey M P, Hawkins M M et al.. Risk of venous thromboembolism in users of hormone replacement therapy.  Lancet. 1996;  348 977-980
• 40 Shiffman M A. Estrogen and thromboembolic problems.  Plast Reconstr Surg. 2002;  110 713-715